Global Oral Antidiabetic Agents Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Oral Antidiabetic Agents Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Sulfonylureas
  • 1.4.3 Meglitinides
  • 1.4.4 Biguanides
  • 1.4.5 Thiazolidinediones
  • 1.4.6 Alpha-glucosidase Inhibitors
• 1.5 Market by Application
  • 1.5.1 Global Oral Antidiabetic Agents Market Share by Application (2014-2025)
  • 1.5.2 Home Use
  • 1.5.3 Medical Institutions
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Oral Antidiabetic Agents Market Size
• 2.2 Oral Antidiabetic Agents Growth Trends by Regions
  • 2.2.1 Oral Antidiabetic Agents Market Size by Regions (2014-2025)
  • 2.2.2 Oral Antidiabetic Agents Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Oral Antidiabetic Agents Market Size by Manufacturers
  • 3.1.1 Global Oral Antidiabetic Agents Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Oral Antidiabetic Agents Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Oral Antidiabetic Agents Market Concentration Ratio (CR5 and HHI)
• 3.2 Oral Antidiabetic Agents Key Players Head office and Area Served
• 3.3 Key Players Oral Antidiabetic Agents Product/Solution/Service
• 3.4 Date of Enter into Oral Antidiabetic Agents Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Oral Antidiabetic Agents Market Size by Type (2014-2019)
• 4.2 Global Oral Antidiabetic Agents Market Size by Application (2014-2019)

5 United States

• 5.1 United States Oral Antidiabetic Agents Market Size (2014-2019)
• 5.2 Oral Antidiabetic Agents Key Players in United States
• 5.3 United States Oral Antidiabetic Agents Market Size by Type
• 5.4 United States Oral Antidiabetic Agents Market Size by Application

6 Europe

• 6.1 Europe Oral Antidiabetic Agents Market Size (2014-2019)
• 6.2 Oral Antidiabetic Agents Key Players in Europe
• 6.3 Europe Oral Antidiabetic Agents Market Size by Type
• 6.4 Europe Oral Antidiabetic Agents Market Size by Application

7 China

• 7.1 China Oral Antidiabetic Agents Market Size (2014-2019)
• 7.2 Oral Antidiabetic Agents Key Players in China
• 7.3 China Oral Antidiabetic Agents Market Size by Type
• 7.4 China Oral Antidiabetic Agents Market Size by Application

8 Japan

• 8.1 Japan Oral Antidiabetic Agents Market Size (2014-2019)
• 8.2 Oral Antidiabetic Agents Key Players in Japan
• 8.3 Japan Oral Antidiabetic Agents Market Size by Type
• 8.4 Japan Oral Antidiabetic Agents Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Oral Antidiabetic Agents Market Size (2014-2019)
• 9.2 Oral Antidiabetic Agents Key Players in Southeast Asia
• 9.3 Southeast Asia Oral Antidiabetic Agents Market Size by Type
• 9.4 Southeast Asia Oral Antidiabetic Agents Market Size by Application

10 India

• 10.1 India Oral Antidiabetic Agents Market Size (2014-2019)
• 10.2 Oral Antidiabetic Agents Key Players in India
• 10.3 India Oral Antidiabetic Agents Market Size by Type
• 10.4 India Oral Antidiabetic Agents Market Size by Application

11 Central & South America

• 11.1 Central & South America Oral Antidiabetic Agents Market Size (2014-2019)
• 11.2 Oral Antidiabetic Agents Key Players in Central & South America
• 11.3 Central & South America Oral Antidiabetic Agents Market Size by Type
• 11.4 Central & South America Oral Antidiabetic Agents Market Size by Application

12 International Players Profiles

• 12.1 Novo Nordisk
  • 12.1.1 Novo Nordisk Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Oral Antidiabetic Agents Introduction
  • 12.1.4 Novo Nordisk Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.1.5 Novo Nordisk Recent Development
• 12.2 Eli Lilly
  • 12.2.1 Eli Lilly Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Oral Antidiabetic Agents Introduction
  • 12.2.4 Eli Lilly Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.2.5 Eli Lilly Recent Development
• 12.3 Sanofi
  • 12.3.1 Sanofi Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Oral Antidiabetic Agents Introduction
  • 12.3.4 Sanofi Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.3.5 Sanofi Recent Development
• 12.4 Roche
  • 12.4.1 Roche Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Oral Antidiabetic Agents Introduction
  • 12.4.4 Roche Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.4.5 Roche Recent Development
• 12.5 Teva
  • 12.5.1 Teva Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Oral Antidiabetic Agents Introduction
  • 12.5.4 Teva Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.5.5 Teva Recent Development
• 12.6 AstraZeneca
  • 12.6.1 AstraZeneca Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Oral Antidiabetic Agents Introduction
  • 12.6.4 AstraZeneca Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.6.5 AstraZeneca Recent Development
• 12.7 Wockhardt UK
  • 12.7.1 Wockhardt UK Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Oral Antidiabetic Agents Introduction
  • 12.7.4 Wockhardt UK Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.7.5 Wockhardt UK Recent Development
• 12.8 Merck
  • 12.8.1 Merck Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Oral Antidiabetic Agents Introduction
  • 12.8.4 Merck Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.8.5 Merck Recent Development
• 12.9 Pfizer
  • 12.9.1 Pfizer Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Oral Antidiabetic Agents Introduction
  • 12.9.4 Pfizer Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.9.5 Pfizer Recent Development
• 12.10 Cipla
  • 12.10.1 Cipla Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Oral Antidiabetic Agents Introduction
  • 12.10.4 Cipla Revenue in Oral Antidiabetic Agents Business (2014-2019)
  • 12.10.5 Cipla Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer